Antiviral medications for influenza in adults
Pro Research Analysisby 
Searched over 200M research papers
Overview of Antiviral Medications for Influenza in Adults
Antiviral medications are a key tool for treating and preventing influenza in adults, especially in high-risk populations. The main classes of antivirals include neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir), the endonuclease inhibitor baloxavir, and older M2 inhibitors (amantadine, rimantadine). Their effectiveness, safety, and recommended use vary based on patient risk factors and timing of administration.
Effectiveness of Neuraminidase Inhibitors and Baloxavir
Symptom Relief and Complication Reduction
Neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir) and baloxavir are most effective when started within 48 hours of symptom onset. These drugs can shorten the duration of influenza symptoms compared to placebo, with zanamivir associated with the shortest time to symptom relief and baloxavir linked to a lower risk of influenza-related complications in both adults and children 2410. Baloxavir, in particular, probably reduces the risk of hospital admission for high-risk patients and may reduce symptom duration without increasing adverse events .
Hospitalization and Mortality
Antiviral treatment, especially with oseltamivir, can reduce the risk of hospitalization, particularly in older adults and those with underlying health conditions 36. However, for low-risk patients, all antiviral drugs have little or no effect on mortality or hospital admission . Baloxavir may offer some benefit in reducing hospital admissions for high-risk groups .
Safety and Adverse Events
Oseltamivir is generally well tolerated but may increase the risk of nausea and other mild adverse events 110. Baloxavir is associated with fewer adverse events compared to oseltamivir . Amantadine and rimantadine, older M2 inhibitors, are less favored due to higher rates of side effects such as nausea, insomnia, and hallucinations, and are generally discouraged for routine use .
Prophylaxis and Transmission Prevention
Antivirals can be used for post-exposure prophylaxis in specific populations to prevent influenza transmission, especially in household contacts and high-risk groups 12. Oseltamivir and zanamivir have demonstrated efficacy in reducing the spread of influenza when used as prophylaxis .
Special Considerations for Older Adults
Older adults are particularly vulnerable to influenza complications. Oseltamivir has the most evidence for reducing mortality and complications in this group, including those in hospitals and long-term care facilities. Peramivir and baloxavir are alternatives, with baloxavir being well tolerated and peramivir offering rapid symptom relief .
Emerging and Future Antiviral Agents
New antiviral agents in late-phase clinical trials target different stages of the influenza virus life cycle, including host cell components and viral polymerase. Some investigational drugs, such as nitazoxanide, DAS181, and T-705, may offer improved effectiveness, especially when used in combination with existing antivirals like oseltamivir 589. Combination therapy and new drug classes are being explored to address resistance and improve outcomes, particularly in severe or complicated cases 58.
Conclusion
For adults with influenza, early initiation of neuraminidase inhibitors or baloxavir can shorten illness duration and reduce complications, especially in high-risk groups. Oseltamivir remains the most versatile and widely studied option, while baloxavir offers a favorable safety profile and may further reduce hospital admissions in high-risk patients. Amantadine and rimantadine are no longer recommended due to limited effectiveness and higher rates of adverse events. Ongoing research into new antiviral agents and combination therapies may further improve influenza management in the future 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Antivirals for influenza in healthy adults: systematic review.
Amantadine and rimantadine are ineffective in seasonal influenza control, and neuraminidase inhibitors should only be used in serious epidemics or pandemics.
Modeling the potential impacts of outpatient antiviral treatment in reducing influenza-associated hospitalizations in the United States
Outpatient antiviral treatment can significantly reduce influenza-associated hospitalizations, particularly in older adults and those at higher risk of complications.
Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children
Zanamivir is the most effective antiviral agent for shortening influenza symptoms, while baloxavir is associated with fewer complications in healthy adults and children.
Developing new antiviral agents for influenza treatment: what does the future hold?
New antiviral agents are urgently needed to overcome current limitations in influenza treatment, with potential targets including polymerase inhibitors and attachment inhibitors.
DOI